Overview

BKM120 for Patients With PI3K-activated Tumors

Status:
Completed
Trial end date:
2016-09-26
Target enrollment:
Participant gender:
Summary
The purpose of this signal seeking study was is to determine whether treatment with BKM120 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals